204 related articles for article (PubMed ID: 21750735)
1. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
[TBL] [Abstract][Full Text] [Related]
2. Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.
Gafar F; Arifin H; Jurnalis YD; Yani FF; Fitria N; Alffenaar JC; Wilffert B
Pediatr Infect Dis J; 2019 Jan; 38(1):50-53. PubMed ID: 30234790
[TBL] [Abstract][Full Text] [Related]
3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
4. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.
Zhang S; Pan H; Peng X; Lu H; Fan H; Zheng X; Xu G; Wang M; Wang J
J Gastroenterol Hepatol; 2016 Feb; 31(2):409-16. PubMed ID: 26243373
[TBL] [Abstract][Full Text] [Related]
5. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
6. Changing Trajectories of Alanine Aminotransferase and Risk of Antituberculosis Drug-Induced Liver Injury in Chinese Patients: A Cohort Study.
Chen X; Pan H; Hao Z; Yi H; Tang S
J Clin Pharmacol; 2024 Jul; 64(7):840-848. PubMed ID: 38436510
[TBL] [Abstract][Full Text] [Related]
7. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
8. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients.
Wu S; Xia Y; Lv X; Tang S; Yang Z; Zhang Y; Wang X; Hu D; Liu F; Yuan Y; Tu D; Sun F; Zhou L; Zhan S
J Gastroenterol Hepatol; 2015 Mar; 30(3):540-5. PubMed ID: 25160904
[TBL] [Abstract][Full Text] [Related]
9. Absence of significant association between UGT2B4 genetic variants and the susceptibility to anti-tuberculosis drug-induced liver injury in a Western Chinese population.
Chen H; Jiao L; Zhou J; Bai H; Lyu M; Wu T; Wu L; Song J; Liu T; Yan H; Ying B
J Clin Pharm Ther; 2021 Feb; 46(1):66-73. PubMed ID: 32170986
[TBL] [Abstract][Full Text] [Related]
10. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
[TBL] [Abstract][Full Text] [Related]
11. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients.
Zhang D; Hao J; Hou R; Yu Y; Hu B; Wei L
J Clin Pharm Ther; 2020 Jun; 45(3):561-569. PubMed ID: 32364660
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta 1 polymorphisms and anti-tuberculosis drug-induced liver injury. Polymorphisms in TGFβ1 and its relationship with anti-tuberculosis drug-induced liver injury.
Wu S; Wang Y; Zhang M; Wang M; He JQ
Therapie; 2019 Jun; 74(3):399-406. PubMed ID: 30093157
[TBL] [Abstract][Full Text] [Related]
13. The role of regular liver function monitoring in antituberculosis drug-induced liver injury.
Chang TE; Huang YS; Su WJ; Perng CL; Huang YH; Hou MC
J Chin Med Assoc; 2019 Jul; 82(7):535-540. PubMed ID: 31274784
[TBL] [Abstract][Full Text] [Related]
14. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China.
Wu S; Xia Y; Lv X; Zhang Y; Tang S; Yang Z; Tu D; Deng P; Cheng S; Wang X; Yuan Y; Liu F; Hu D; Zhan S
BMC Public Health; 2012 Jun; 12():454. PubMed ID: 22712786
[TBL] [Abstract][Full Text] [Related]
15. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study.
Chen S; Pan H; Chen Y; Lu L; He X; Chen H; Chen R; Zhan S; Tang S
Sci Rep; 2019 Oct; 9(1):14311. PubMed ID: 31586142
[TBL] [Abstract][Full Text] [Related]
16. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
17. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Chen G; Wu SQ; Feng M; Wang Y; Wu JC; Ji GY; Zhang MM; Liu QQ; He JQ
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):434-438. PubMed ID: 28934901
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.
Lv X; Tang S; Xia Y; Wang X; Yuan Y; Hu D; Liu F; Wu S; Zhang Y; Yang Z; Tu D; Chen Y; Deng P; Ma Y; Chen R; Zhan S
PLoS One; 2013; 8(6):e65037. PubMed ID: 23750225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
